PMID- 31195212
OWN - NLM
STAT- MEDLINE
DCOM- 20190716
LR  - 20190716
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 77
DP  - 2019 Jul
TI  - Management of adverse events associated with tyrosine kinase inhibitors: 
      Improving outcomes for patients with hepatocellular carcinoma.
PG  - 20-28
LID - S0305-7372(19)30067-2 [pii]
LID - 10.1016/j.ctrv.2019.05.004 [doi]
AB  - Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. 
      Sorafenib, regorafenib, lenvatinib and cabozantinib are tyrosine kinase 
      inhibitors (TKIs) that target, in part, vascular endothelial growth factor 
      receptors, and are approved in various regions of the world for the treatment of 
      advanced HCC. All these agents are associated with a range of adverse events 
      (AEs) that can have a substantial impact on patients' health-related quality of 
      life. Fatigue, diarrhoea, hand-foot skin reaction, nausea, vomiting, decreased 
      appetite, hypertension and weight loss are among the most common AEs experienced 
      with these four TKIs. In this review, we discuss strategies for the management of 
      these AEs in patients with advanced HCC, with the aim of maximizing treatment 
      benefits and minimizing the need for TKI treatment discontinuation. We also 
      consider potential TKI-drug interactions and discuss the use of TKIs in patients 
      with liver dysfunction or who have experienced tumour recurrence after liver 
      transplantation. Use of appropriate AE management strategies and avoidance of 
      contraindicated drugs should help patients with advanced HCC to achieve optimal 
      outcomes with TKIs.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Rimassa, Lorenza
AU  - Rimassa L
AD  - Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical 
      and Research Center - IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
FAU - Danesi, Romano
AU  - Danesi R
AD  - Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and 
      Experimental Medicine, University of Pisa, Via Roma 67, Pisa, Italy.
FAU - Pressiani, Tiziana
AU  - Pressiani T
AD  - Medical Oncology and Hematology Unit, Humanitas Cancer Center, Humanitas Clinical 
      and Research Center - IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy.
FAU - Merle, Philippe
AU  - Merle P
AD  - Department of Hepatology, Hopital de la Croix-Rousse, Hospices Civils de Lyon, 
      Universite Lyon 1, 103 Grande rue de la Croix Rousse, Lyon, France. Electronic 
      address: philippe.merle@inserm.fr.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190515
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Protein Kinase Inhibitors)
SB  - IM
MH  - Carcinoma, Hepatocellular/*drug therapy/enzymology
MH  - Drug-Related Side Effects and Adverse Reactions/etiology/prevention & 
      control/*therapy
MH  - Humans
MH  - Liver Neoplasms/*drug therapy/enzymology
MH  - Protein Kinase Inhibitors/administration & dosage/*adverse effects
OTO - NOTNLM
OT  - Advanced hepatocellular carcinoma
OT  - Adverse event management
OT  - Cabozantinib
OT  - Lenvatinib
OT  - Regorafenib
OT  - Sorafenib
EDAT- 2019/06/14 06:00
MHDA- 2019/07/17 06:00
CRDT- 2019/06/14 06:00
PHST- 2019/01/22 00:00 [received]
PHST- 2019/05/10 00:00 [revised]
PHST- 2019/05/13 00:00 [accepted]
PHST- 2019/06/14 06:00 [pubmed]
PHST- 2019/07/17 06:00 [medline]
PHST- 2019/06/14 06:00 [entrez]
AID - S0305-7372(19)30067-2 [pii]
AID - 10.1016/j.ctrv.2019.05.004 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2019 Jul;77:20-28. doi: 10.1016/j.ctrv.2019.05.004. Epub 2019 
      May 15.